Investors/Media

May 25, 2023
Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 25, 2023-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing
May 24, 2023
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 24, 2023-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier
May 22, 2023
Javier Szwarcberg , M.D., M.P.H., Chief Executive Officer, accepted the Corporate Partner Award SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 22, 2023-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies
Displaying 1 - 10 of 18